Articles tagged "Rejection"

2020 American Transplant Congress
Operational Tolerance in Kidney Transplant Recipients: Tomogram Transcriptomic Study
O. Viklicky¹, J. Klema², P. Mrazova¹, D. Abramowitz³, M. Abramowicz⁴, A. Massart³, P. Hruba¹
¹Institute for Clinical and Experimental Medicine, Prague, Czech Republic, ²Czech Technical University, Prague, Czech Republic, ³Antwerp University Hospital, Antwerp, Belgium, ⁴Université Libre de Bruxelles, Brussels, Belgium
*Purpose: TOMOGRAM is a European multicenter study, that aims to identify transcriptomic and genomic signatures of operational tolerance (OT) in a recently identified cohort of…
2020 American Transplant Congress
Single Dose Rituximab and Anti-Thymocyte Globulin (ATG) Induction in Hypersensitized Kidney Transplant Recipients
A. X. Wang, U. Wang, S. Busque, C. R. Lenihan
Stanford University School of Medicine, Stanford, CA
*Purpose: Hypersensitized kidney transplant recipients (calculated panel reactive antibody (cPRA) ≥98%) may represent a population at high risk of posttransplant immunologic events. While access to…
2020 American Transplant Congress
Association of Congenital Anomalies of the Kidney and Urinary Tract with Urinary Tract Infection and Graft Rejection in Pediatric Kidney Transplant Recipients
M. Bock, D. Han, A. Sikora, K. Mckinnon, S. Hecht, M. Chandran, V. Vemulakonda
Children's Hospital Colorado, Denver, CO
*Purpose: Congenital anomalies of the kidney and urinary tract (CAKUT) are a leading cause of pediatric end-stage renal disease (ESRD). Prior studies have shown an…
2020 American Transplant Congress
Torque Teno Virus Level for Risk Stratification of Subclinical Graft Rejection at 12 Months after Kidney Transplantation – An Prospective Observational Cohort Study
K. Doberer, E. Puchhammer, G. Böhmig, G. Bond
Medical University Vienna, Vienna, Austria
*Purpose: Non-invasive monitoring strategies are insufficient to detect patients at risk for subclinical graft rejection after kidney transplantation. The highly prevalent and non-pathogenic Torque Teno…
2020 American Transplant Congress
Routine Human Renal Allograft Biopsies Analyzed for mRNA Content with a Novel Nanostring mRNA Human Organ Transplant (HOT) Panel
I. Rosales¹, R. Smith¹, E. Acheampong¹, T. Kawai¹, T. Tsuji², K. Hotta³, R. Colvin¹
¹Massachusetts General Hospital, Boston, MA, ²Sapporo City General Hospital, Sapporo, Japan, ³Hokkaido University Hospital, Sapporo, Japan
*Purpose: In 2019 a Banff Working Group and Nanostring Technologies developed a panel of 770 mRNA probes for assessment of human organ allografts, based on…
2020 American Transplant Congress
CD38 Antibody Daratumumab for the Treatment of Chronic Antibody-Mediated Kidney Allograft Rejection
K. Doberer¹, J. Kläger², G. A. Gualdoni¹, K. Mayer¹, F. Eskandary¹, H. Agis³, T. Reiter¹, R. Reindl-Schwaighofer¹, M. Wahrmann¹, G. Cohen¹, H. Haslacher⁴, G. Bond¹, I. Simonitsch-Klupp⁵, I. Farkash⁶, P. Halloran⁷, G. A. Böhmig¹
¹Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Dept. of Clin. Pathology, Medical University of Vienna, Vienna, Austria, ³Department of Medicine I, Medical University of Vienna, Vienna, Austria, ⁴Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ⁵Department of Pathology, Medical University of Vienna, Vienna, Austria, ⁶Dept. of Pathology, University of Michigan, Ann Arbor, MI, ⁷Alberta Transplant Applied Genomics Centre, ATAGC, University of Alberta, Edmonton, AB, Canada
*Purpose: Late antibody-mediated rejection (ABMR) is a major cause of transplant failure. Potential therapeutic targets are plasma cells (PC) and natural killer (NK) cells expressing…
2020 American Transplant Congress
Five Year Patient Important Outcomes of Treated Acute Rejections Diagnosed with Protocol and Clinical Biopsy after Pancreas Transplant Alone for Type 1 Diabetes
Y. C. Kudva, S. R. Rizvi, R. Kaur, B. H. Smith, S. Batthula, P. G. Dean, A. Kukla, W. K. Kremers, M. D. Stegall
Mayo Clinic, Rochester, MN
*Purpose: STUDY PURPOSE: Acute rejection (AR) after Pancreas Transplant alone (PTA) continues to be a significant morbidity. We compared the outcomes of PTA recipients treated…
2020 American Transplant Congress
Anti-T Lymphocyte Immunoglobulins versus Basiliximab in Highly Sensitized Kidney-Transplant Patients without Preformed DSAs: The Satir Study
N. Kamar¹, L. Couzi², L. Albano³, A. Durrbach⁴, V. Pernin⁵, L. Esposito¹, M. Lequintrec⁵, P. Merville², A. Del Bello¹
¹Toulouse University Hospital, Toulouse, France, ²Bordeaux University Hospital, Bordeaux, France, ³Nice University Hospital, Nice, France, ⁴Henri Mondor University Hospital, Paris, France, ⁵Montpellier University Hospital, Montpellier, France
*Purpose: Two prospective studies that were performed before the era of highly sensitive solid-phase assays have shown a lower incidence of acute rejection in highly…
2019 American Transplant Congress
The Use of mTOR Inhibitors Prevents Acute Cellular Rejection in Kidney Transplantation on Belatacept Therapy
J. Shoji, J. C. Leung, Q. Tang, J. P. Roberts, F. Vincenti
University of California San Francisco, San Francisco, CA
*Purpose: Belatacept is a costimulatory blocker that is used as de novo maintenance immunosuppression in kidney transplantation to avoid toxic effects of calcineurin inhibitors and…
2019 American Transplant Congress
Clazakizumab (CLZ, Anti-IL-6 Antibody) and Tocilizumab (TCZ, Anti-IL-6 Receptor [r] Antibody) Treatments Differentially Affect IL-6/IL-6R Signaling by Modulating Soluble IL-6R (sIL-6R) and gp130 (sgp130) in Kidney Transplant Patients (KTx Pts) Treated for Chronic Antibody-Mediated Rejection (cABMR)
B. Shin, S. Ge, A. Petrosyan, N. F. Ammerman, A. A. Vo, S. C. Jordan, M. Toyoda
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have reported successful use of TCZ for cABMR treatment in HLA-sensitized KTx Pts. CLZ is 3-120 times more potent than TCZ in IL-6/IL-6R…